Developers of the world's first candidate malaria vaccine said that new tests have shown that it protects a third of six- to 12-week-old infants, which is less than its effect in older babies. The "modest" result came as a surprise to researchers working hard on a drug to combat the mosquito-born disease that kills hundreds of thousands of children per year. The trial vaccine, RTS,S, is made by British pharmaceutical giant GlaxoSmithKline, whose chief ...
via Medindia Health News More READ
No comments:
Post a Comment